Explore

Trendline Trendline
Biogen and Denali Halt Parkinson's Drug Development After Phase 2 Trial Failure

Biogen and Denali Halt Parkinson's Drug Development After Phase 2 Trial Failure

Biogen and Denali Halt Parkinson's Drug Development After Phase 2 Trial Failure
Trendline Trendline
Herantis Partners with Indivi for Digital Biomarker Integration in HER-096 Phase II Trial

Herantis Partners with Indivi for Digital Biomarker Integration in HER-096 Phase II Trial

Herantis Partners with Indivi for Digital Biomarker Integration in HER-096 Phase II Trial
Trendline Trendline
Verdiva Bio to Present Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions

Verdiva Bio to Present Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions

Verdiva Bio to Present Preclinical Data on Obesity Drug Candidates at ADA Scientific Sessions
Trendline Trendline
FDA Veteran Paz Vellanki Joins Precision for Medicine, Enhancing Regulatory Expertise

FDA Veteran Paz Vellanki Joins Precision for Medicine, Enhancing Regulatory Expertise

FDA Veteran Paz Vellanki Joins Precision for Medicine, Enhancing Regulatory Expertise
Trendline Trendline
Qihan Biotech Receives FDA Clearance for Innovative CAR-T Therapy for Autoimmune Diseases

Qihan Biotech Receives FDA Clearance for Innovative CAR-T Therapy for Autoimmune Diseases

Qihan Biotech Receives FDA Clearance for Innovative CAR-T Therapy for Autoimmune Diseases
Trendline Trendline
Aulos Bioscience's Imneskibart Shows Promise in Refractory Metastatic Melanoma

Aulos Bioscience's Imneskibart Shows Promise in Refractory Metastatic Melanoma

Aulos Bioscience's Imneskibart Shows Promise in Refractory Metastatic Melanoma
Trendline Trendline
Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer

Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer

Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer
Trendline Trendline
Parabilis Biotech Files for IPO to Fund Cancer Drug Trials

Parabilis Biotech Files for IPO to Fund Cancer Drug Trials

Parabilis Biotech Files for IPO to Fund Cancer Drug Trials
Trendline Trendline
Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform

Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform

Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform
Trendline Trendline
Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial

Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial

Sanofi's Experimental Therapy for AATD Shows Promise in Phase 2 Trial
Trendline Trendline
FDA Accepts sNDA and Grants Priority Review to AQNEURSA for Ataxia-Telangiectasia

FDA Accepts sNDA and Grants Priority Review to AQNEURSA for Ataxia-Telangiectasia

FDA Accepts sNDA and Grants Priority Review to AQNEURSA for Ataxia-Telangiectasia
Trendline Trendline
Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment

Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment

Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment